Edwards Martin

CIK 00016400736 companiesLONDON, X0

SEC Profile

Transactions

Companies

Filings

CIK

0001640073

Recent Transactions

50 trades

Disposition to Issuer
Verona Pharma plc$VRNA
Ordinary Shares
2025-10-07−72,000→ 0 total
Disposition to Issuer
Verona Pharma plc$VRNA
Share Options (Right to Buy)
2025-10-07−64,000→ 0 total
Disposition to Issuer
Verona Pharma plc$VRNA
Share Options (Right to Buy)
2025-10-07−240,000→ 0 total
Disposition to Issuer
Verona Pharma plc$VRNA
Share Options (Right to Buy)
2025-10-07−96,000→ 0 total
Disposition to Issuer
Verona Pharma plc$VRNA
Share Options (Right to Buy)
2025-10-07−200,000→ 0 total
Disposition to Issuer
Verona Pharma plc$VRNA
Ordinary Shares
2025-10-07−157,992→ 0 total
Exercise/Conversion
Verona Pharma plc$VRNA
Ordinary Shares
2025-10-07+72,000→ 72,000 total
Exercise/Conversion
Verona Pharma plc$VRNA
Restricted Share Unit
2025-10-07−72,000→ 0 total
Exercise/Conversion
Verona Pharma plc$VRNA
Ordinary Shares
2025-08-01+24,000→ 168,800 total
Exercise/Conversion
Verona Pharma plc$VRNA
Restricted Stock Units
2025-08-01−24,000→ 72,000 total
Sale
Verona Pharma plc$VRNA
Ordinary Shares
2025-08-01$13.14/sh−10,808→ 157,992 total
Award
Verona Pharma plc$VRNA
Restricted Share Units
2025-04-25+96,000→ 96,000 total
Disposition to Issuer
Morphic Holding, Inc.
Stock Option (Right to Buy)
2024-08-16−9,996→ 0 total
Disposition to Issuer
Morphic Holding, Inc.
Stock Option (Right to Buy)
2024-08-16−24,000→ 0 total
Disposition to Issuer
Morphic Holding, Inc.
Common Stock
2024-08-16−2,376→ 0 total
Disposition to Issuer
Morphic Holding, Inc.
Stock Option (Right to Buy)
2024-08-16−12,535→ 0 total
Disposition to Issuer
Morphic Holding, Inc.
Stock Option (Right to Buy)
2024-08-16−17,550→ 0 total
Disposition to Issuer
Morphic Holding, Inc.
Stock Option (Right to Buy)
2024-08-16−23,168→ 0 total
Award
Inozyme Pharma, Inc.
Stock Option (right to buy)
2024-06-18+28,000→ 28,000 total
Award
Morphic Holding, Inc.
Common Stock
2024-06-04+23,168→ 23,168 total
Award
Verona Pharma plc$VRNA
Share Options (Right to Buy)
2024-04-29+240,000→ 240,000 total
Purchase
Verona Pharma plc$VRNA
Ordinary Shares
2023-11-20$1.84/sh+33,736→ 144,800 total
Purchase
Morphic Holding, Inc.
Common Stock
2023-11-13$20.54/sh+2,376→ 2,376 total
Disposition to Issuer
REATA PHARMACEUTICALS INC
Stock Option (right to buy)
2023-09-26−169→ 0 total
Disposition to Issuer
REATA PHARMACEUTICALS INC
Class A common stock
2023-09-26−6,116→ 0 total
Disposition to Issuer
REATA PHARMACEUTICALS INC
Stock Option (right to buy)
2023-09-26−10,000→ 0 total
Disposition to Issuer
REATA PHARMACEUTICALS INC
Stock Option (right to buy)
2023-09-26−6,300→ 0 total
Disposition to Issuer
REATA PHARMACEUTICALS INC
Stock Option (right to buy)
2023-09-26−5,000→ 0 total
Disposition to Issuer
REATA PHARMACEUTICALS INC
Stock Option (right to buy)
2023-09-26−99→ 0 total
Disposition to Issuer
REATA PHARMACEUTICALS INC
Stock Option (right to buy)
2023-09-26−520→ 0 total
Disposition to Issuer
REATA PHARMACEUTICALS INC
Stock Option (right to buy)
2023-09-26−5,620→ 0 total
Disposition to Issuer
REATA PHARMACEUTICALS INC
Stock Option (right to buy)
2023-09-26−2,137→ 0 total
Award
Inozyme Pharma, Inc.
Stock Option (right to buy)
2023-06-13+16,000→ 16,000 total
Award
REATA PHARMACEUTICALS INC
Class A common stock
2023-06-07$93.61/sh+1,682→ 6,116 total
Award
REATA PHARMACEUTICALS INC
Stock Option (right-to-buy)
2023-06-07$73.68/sh+169→ 169 total
Award
REATA PHARMACEUTICALS INC
Stock Option (right-to-buy)
2023-06-07+2,137→ 2,137 total
Award
REATA PHARMACEUTICALS INC
Class A common stock
2023-06-07$93.61/sh+133→ 4,434 total
Award
Morphic Holding, Inc.
Director Stock Option (Right to Buy)
2023-06-01+12,535→ 12,535 total
Award
Verona Pharma plc$VRNA
Share Options (Right to Buy)
2023-04-28+96,000→ 96,000 total
Award
Inozyme Pharma, Inc.
Stock Option (right to buy)
2022-06-10+9,367→ 9,367 total
Award
REATA PHARMACEUTICALS INC
Stock Option (right-to-buy)
2022-06-08$24.02/sh+520→ 520 total
Award
REATA PHARMACEUTICALS INC
Class A common stock
2022-06-08$34.76/sh+359→ 418 total
Award
REATA PHARMACEUTICALS INC
Class A common stock
2022-06-08$34.76/sh+3,883→ 4,301 total
Award
REATA PHARMACEUTICALS INC
Stock Option (right-to-buy)
2022-06-08+5,620→ 5,620 total
Award
Morphic Holding, Inc.
Director Stock Option (Right to Buy)
2022-06-08+17,550→ 17,550 total
Award
Verona Pharma plc$VRNA
Share Options (Right to Buy)
2022-04-28+200,000→ 200,000 total
Award
REATA PHARMACEUTICALS INC
Stock Option (right to buy)
2022-01-03$16.14/sh+99→ 99 total
Award
REATA PHARMACEUTICALS INC
Class A common stock
2022-01-03$27.32/sh+59→ 59 total
Award
KalVista Pharmaceuticals, Inc.
Director Stock Option (Right to Buy)
2021-09-30+10,000→ 10,000 total
Award
Verona Pharma plc$VRNA
Share Options (Right to Buy)
2021-08-09+64,000→ 64,000 total

Companies

Recent Filings

Address

3 MORE LONDON RIVERSIDE

LONDON, X0, SE1 2RE

View on SEC.gov